Related Experiment Video
Updated: May 3, 2026

08:45
Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
Published on: November 13, 2012
13.5K
Abstract:
Results from a phase I study of Infinity Pharmaceuticals' IPI-145, which inhibits both δ and γ isoforms of phosphoinositide3-kinase, suggest the drug is safe and effective in patients with advanced chronic lymphocytic leukemia.

